Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis
NCT00047645 is registered in ClinicalTrials.gov with InterMune as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis
- Lead sponsor
- InterMune
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 30, 2000
- Completion date
- December 31, 2002
- Enrollment
- 330 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.